Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination.
The filing of the preliminary proxy statement initiates the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders. “This is an important milestone and begins the process of transitioning Sema4 into an independent public company and leader in the clinical genomics space. There is tremendous growth potential ahead for the company and we are excited by the opportunities that will be enabled by this transaction,” commented Eli Casdin, Chief Executive Officer of CM Life Sciences.
“As each day goes by, Sema4 grows as a leader in patient-centered genomic and clinical data,” remarked Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “Meanwhile, we continue to be on track to achieve the 2021 financial and strategic goals and importantly build a business that is powered to execute on the long term potential of an AI-powered platform to health system partners, providers and their patients.”
“We look forward to consummating the transaction following SEC review and approval from our shareholders, which is anticipated by the end of July,” said Keith Meister, Chairman of CM Life Sciences.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.